View in EDS

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Saved in:
Bibliographic Details
Title: Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
Authors: Pradeep C-; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.; Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA., Zeisel A; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel., Köstler WJ; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.; Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Lauriola M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Jacob-Hirsch J; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Haibe-Kains B; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.; Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium., Amariglio N; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Ben-Chetrit N; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Emde A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Solomonov I; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel., Neufeld G; Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel., Piccart M; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium., Sagi I; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel., Sotiriou C; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium., Rechavi G; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Domany E; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel., Desmedt C; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium., Yarden Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. yosef.yarden@weizmann.ac.il.
Source: Oncogene [Oncogene] 2024 Apr; Vol. 43 (17), pp. 1317.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38418546
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pradeep+C-%22">Pradeep C-</searchLink>; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.; Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Zeisel+A%22">Zeisel A</searchLink>; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Köstler+WJ%22">Köstler WJ</searchLink>; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.; Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Lauriola+M%22">Lauriola M</searchLink>; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Jacob-Hirsch+J%22">Jacob-Hirsch J</searchLink>; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Haibe-Kains+B%22">Haibe-Kains B</searchLink>; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.; Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Amariglio+N%22">Amariglio N</searchLink>; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Ben-Chetrit+N%22">Ben-Chetrit N</searchLink>; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Emde+A%22">Emde A</searchLink>; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Solomonov+I%22">Solomonov I</searchLink>; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Neufeld+G%22">Neufeld G</searchLink>; Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Piccart+M%22">Piccart M</searchLink>; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Sagi+I%22">Sagi I</searchLink>; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Sotiriou+C%22">Sotiriou C</searchLink>; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Rechavi+G%22">Rechavi G</searchLink>; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Domany+E%22">Domany E</searchLink>; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.<br /><searchLink fieldCode="AU" term="%22Desmedt+C%22">Desmedt C</searchLink>; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Yarden+Y%22">Yarden Y</searchLink>; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. yosef.yarden@weizmann.ac.il.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228711562%22">Oncogene</searchLink> [Oncogene] 2024 Apr; Vol. 43 (17), pp. 1317.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8711562 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5594 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209509232%22">09509232 </searchLink><i>NLM ISO Abbreviation: </i>Oncogene <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38418546
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41388-024-02990-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1317
    Titles:
      – TitleFull: Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pradeep C-
      – PersonEntity:
          Name:
            NameFull: Zeisel A
      – PersonEntity:
          Name:
            NameFull: Köstler WJ
      – PersonEntity:
          Name:
            NameFull: Lauriola M
      – PersonEntity:
          Name:
            NameFull: Jacob-Hirsch J
      – PersonEntity:
          Name:
            NameFull: Haibe-Kains B
      – PersonEntity:
          Name:
            NameFull: Amariglio N
      – PersonEntity:
          Name:
            NameFull: Ben-Chetrit N
      – PersonEntity:
          Name:
            NameFull: Emde A
      – PersonEntity:
          Name:
            NameFull: Solomonov I
      – PersonEntity:
          Name:
            NameFull: Neufeld G
      – PersonEntity:
          Name:
            NameFull: Piccart M
      – PersonEntity:
          Name:
            NameFull: Sagi I
      – PersonEntity:
          Name:
            NameFull: Sotiriou C
      – PersonEntity:
          Name:
            NameFull: Rechavi G
      – PersonEntity:
          Name:
            NameFull: Domany E
      – PersonEntity:
          Name:
            NameFull: Desmedt C
      – PersonEntity:
          Name:
            NameFull: Yarden Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1476-5594
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 17
          Titles:
            – TitleFull: Oncogene
              Type: main
ResultId 1